文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

前蛋白转化酶枯草溶菌素9对脓毒症相关血小板活化的影响

[Effect of proprotein convertase subtilisin/kexin type 9 on platelet activation associated with sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论脓毒症患者血清PCSK9水平升高且与血小板计数负相关;动物实验中PCSK9抑制剂预处理可减轻LPS诱导的血小板活化及肺损伤。

该研究包含临床前瞻性观察与动物实验两部分。临床部分纳入57例脓毒症患者和27例健康对照,脓毒症组血清PCSK9水平显著高于健康对照组(232.25±72.21 μg/L vs. 191.72±54.92 μg/L,P<0.05),血小板计数显著低于对照组[146.00(75.50, 204.50)×10^9/L vs. 224.00(194.00, 247.00)×10^9/L,P<0.01];亚组分析显示血小板减少患者PCSK9水平显著高于非血小板减少患者(264.04±60.40 μg/L vs. 215.06±72.95 μg/L,P<0.01),PCSK9与PLT呈显著负相关(r=-0.340,P=0.010)。动物实验中,PCSK9抑制剂预处理(5 mg/kg腹腔注射7天)可减轻LPS(12 mg/kg腹腔注射)诱导的肺组织炎症细胞浸润、肺泡间隔增厚和血小板聚集,显著提高PLT(515.83±46.60×10^9/L vs. 324.83±46.31×10^9/L,P<0.05),降低血小板活化标志物CD62P阳性表达率[(12.15±1.39)% vs.(18.33±2.74)%,P<0.05]及CD40L蛋白表达(0.77±0.08 vs. 1.18±0.10,P<0.05)。作者认为PCSK9对脓毒症血小板活化有一定促进作用,抑制PCSK9可能对改善脓毒症血小板减少

要点

  • 脓毒症患者血清PCSK9水平显著高于健康对照(232.25±72.21 μg/L vs. 191.72±54.92 μg/L,P<0.05),PLT显著低于对照[146.00(75.50, 204.50)×10^9/L vs. 224.00(194.00, 247.00)×10^9/L,P<0.01]。
  • 脓毒症合并血小板减少者PCSK9水平显著高于非血小板减少者(264.04±60.40 μg/L vs. 215.06±72.95 μg/L,P<0.01)。
  • 脓毒症患者血清PCSK9水平与PLT呈显著负相关(r=-0.340,P=0.010)。
  • 动物实验中PCSK9抑制剂预处理(5 mg/kg腹腔注射7天)较LPS组显著提高PLT(515.83±46.60×10^9/L vs. 324.83±46.31×10^9/L,P<0.05)。
  • PCSK9抑制剂预处理较LPS组显著降低血小板活化CD62P阳性表达率[(12.15±1.39)% vs.(18.33±2.74)%]及CD40L蛋白表达(0.77±0.08 vs. 1.18±0.10),均P<0.05。

适用人群与场景

  • 临床部分:2021年1月至10月滨州医学院附属医院重症医学科收治的年龄≥18岁、符合Sepsis-3诊断标准的脓毒症及脓毒症休克患者57例;同期健康受试者27例作为健康对照组。
  • 动物部分:80只雄性C57BL/6小鼠,随机分为对照组、脓毒症模型组(LPS组)、PCSK9抑制剂预处理组(PCSK9抑制剂+LPS组)和PCSK9抑制剂对照组(PCSK9抑制剂组),每组20只。

诊断标准与关键阈值

  • 临床部分血小板减少定义:亚组分析中血小板减少患者(n=20)与非血小板减少患者(n=37)的分组依据为PLT,原文未给出具体界值。

处置流程与药物剂量

  • 动物实验:小鼠脓毒症模型通过腹腔注射LPS 12 mg/kg复制;对照组和PCSK9抑制剂组腹腔注射等量无菌生理盐水。
  • PCSK9抑制剂+LPS组和PCSK9抑制剂组在注射LPS或生理盐水前分别给予PCSK9抑制剂5 mg/kg腹腔注射预处理7天;对照组和LPS组注射等量无菌生理盐水。
  • 临床部分:诊断后1天取静脉血,采用酶联免疫吸附试验(ELISA)测定血清PCSK9水平;记录入院后首次血常规血小板计数(PLT)。

研究设计与关键结果

  • 临床部分为前瞻性研究:脓毒症组57例,健康对照组27例;脓毒症组血清PCSK9水平显著高于健康对照组(232.25±72.21 μg/L vs. 191.72±54.92 μg/L,P<0.05),PLT显著低于健康对照组[146.00(75.50, 204.50)×10^9/L vs. 224.00(194.00, 247.00)×10^9/L,P<0.01]。
  • 亚组分析:血小板减少患者(n=20)血清PCSK9水平显著高于非血小板减少患者(n=37;264.04±60.40 μg/L vs. 215.06±72.95 μg/L,P<0.01)。
  • 相关性分析:脓毒症患者血清PCSK9水平与PLT呈显著负相关(r=-0.340,P=0.010)。
  • 动物实验:对照组和PCSK9抑制剂组光镜下肺组织未见明显病理改变,两组PLT、血小板活化及血浆CD40L蛋白表达差异无显著差异。
  • LPS组肺间质大量炎症细胞浸润、肺泡结构明显破坏、肺泡间隔增宽、肺泡腔广泛出血、毛细血管扩张伴出血及血小板聚集,PLT显著降低,血小板活化及血浆CD40L蛋白表达显著升高。
  • PCSK9抑制剂+LPS组较LPS组肺组织炎症细胞浸润一定程度减轻、肺泡间隔增厚减轻、肺组织血小板聚集减少,PLT显著升高(515.83±46.60×10^9/L vs. 324.83±46.31×10^9/L,P<0.05),血小板活化依赖颗粒表面膜蛋白CD62P阳性表达率显著降低[(12.15±1.39)% vs.(18.33±2.74)%],血浆CD40L蛋白表达显著降低(0.77±0.08 vs. 1.18±0.10),均P<0.05。

证据类型、等级与局限

  • 证据类型:临床前瞻性观察研究联合动物实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为PCSK9水平对脓毒症血小板活化有一定促进作用,抑制PCSK9水平可能对改善脓毒症血小板减少所致不良结局有潜在研究价值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) on platelet activation in sepsis.

METHODS: (1) Clinical trial: a prospective study was conducted. Patients with sepsis and septic shock aged ≥ 18 years old who met the diagnostic criteria of Sepsis-3 admitted to the department of intensive care medicine of the Affiliated Hospital of Binzhou Medical College from January to October in 2021 were selected as subjects. Healthy subjects in the same period were taken as healthy control group. Platelet count (PLT) in the first routine blood test after admission was recorded. Venous blood was taken 1 day after diagnosis, and serum PCSK9 level was determined by enzyme-linked immunosorbent assay (ELISA). The differences of PCSK9 level and PLT between the two groups were compared, and subgroup analysis was conducted based on PLT for patients with sepsis. The correlation between PCSK9 level and PLT in septic patients was analyzed by Pearson correlation method. (2) Animal experiment: 80 male C57BL/6 mice were randomly divided into control group, sepsis model group [lipopolysaccharide (LPS) group], PCSK9 inhibitor pretreatment group (PCSK9 inhibitor+LPS group) and PCSK9 inhibitor control group (PCSK9 inhibitor group), with 20 mice in each group. The mouse model of sepsis was reproduced by intraperitoneal injection of LPS 12 mg/kg, and the control group and PCSK9 inhibitor group were intraperitoneally injected with the same amount of sterile normal saline. PCSK9 inhibitor+LPS group and PCSK9 inhibitor group were pretreated with PCSK9 inhibitor 5 mg/kg intraperitoneal injection for 7 days before injection of LPS or normal saline, respectively, and the control group and LPS group were injected with an equal amount of sterile normal saline. The lung tissues were taken for pathological and immunohistochemical observation 24 hours after modeling. Blood was taken from the heart for determining PLT. Platelet activation was detected by flow cytometry. The expression level of platelet-activation marker CD40L was detected by Western blotting.

RESULTS: (1) Clinical trial: there were 57 cases in the sepsis group and 27 cases in the healthy control group. Serum PCSK9 level in the sepsis group was significantly higher than that in the healthy control group (μg/L: 232.25±72.21 vs. 191.72±54.92, P < 0.05), and PLT was significantly lower than that in the healthy control group [×109/L: 146.00 (75.50, 204.50) vs. 224.00 (194.00, 247.00), P < 0.01]. Subgroup analysis showed that the serum PCSK9 level in the thrombocytopenia patients (n = 20) was significantly higher than that in the non-thrombocytopenia patients (n = 37; μg/L: 264.04±60.40 vs. 215.06±72.95, P < 0.01). Correlation analysis showed a significant negative correlation between serum PCSK9 levels and PLT in septic patients (r = -0.340, P = 0.010). (2) Animal experiment: there were no significant pathological changes in lung tissue in the control group and PCSK9 inhibitor group under light microscope, and no significant differences in PLT, platelet activation and plasma CD40L protein expression was found between the two groups. In the LPS group, a large number of inflammatory cells were infiltrated in the pulmonary interstitium, the alveolar structure was damaged obviously, the alveolar septum was widened, the alveolar cavity was extensively bleeding, the capillary dilatation with bleeding and platelet aggregation were found, the PLT was significantly decreased, the platelet activation and the expression level of CD40L protein in plasma were significantly increased. The infiltration of inflammatory cells in lung tissue of mice in the PCSK9 inhibitor+LPS group was reduced to a certain extent, the thickening of alveolar septa was reduced, the platelet aggregation in lung tissue was decreased as compared with the LPS group, the PLT was significantly increased (×109/L: 515.83±46.60 vs. 324.83±46.31, P < 0.05), the platelet activation and the expression level of CD40L protein in plasma were significantly decreased [positive expression rate of platelet activation dependent granule surface facial mask protein CD62P: (12.15±1.39)% vs. (18.33±2.74)%, CD40L protein (CD40L/β-actin): 0.77±0.08 vs. 1.18±0.10, both P < 0.05].

CONCLUSIONS: PCSK9 level has a certain effect on promoting platelet activation in sepsis, and inhibition of PCSK9 level may have potential research value in improving adverse outcomes caused by sepsis thrombocytopenia.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Gao Y, Wang J, Huang X, et al. [Effect of proprotein convertase subtilisin/kexin type 9 on platelet activation associated with sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37593857. doi:10.3760/cma.j.cn121430-20230421-00308

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。